MoleculA Patents
MoleculA has filed 12 patents.
The 3 most popular patent topics include:
- Data management
- Database management systems
- Business intelligence

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
5/26/2020 | 6/27/2023 | Data management, Music software plugin architectures, Application programming interfaces, Database management systems, Information technology management | Grant |
Application Date | 5/26/2020 |
---|---|
Grant Date | 6/27/2023 |
Title | |
Related Topics | Data management, Music software plugin architectures, Application programming interfaces, Database management systems, Information technology management |
Status | Grant |
Latest MoleculA News
Nov 1, 2022
BOSTON, MA — November 1, 2022 — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company has dosed the first patient in its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer. MRT-2359 is a potent, selective and orally bioavailable GSPT1-directed MGD, designed to disrupt protein synthesis in MYC-driven tumors, and lead to anti-tumor activity.“MYC transcription factors are well-defined drivers of human cancers, and disrupting protein translation has emerged as a promising path to address this highly prevalent disease pathway. Dosing the first patient is a significant milestone in developing MRT-2359 as a therapeutic option for MYC-driven cancers,” said Filip Janku, M.D., Ph.D., Chief Medical Officer of Monte Rosa. “We have designed our Phase 1 trial to move efficiently through dose escalation and, by focusing on tumor types where MYC expression is prevalent, to improve our chances of seeing early signals of clinical activity. We are encouraged by the strong preclinical data and hope that MRT-2359 will make a meaningful difference in the lives of patients.”
MoleculA Frequently Asked Questions (FAQ)
When was MoleculA founded?
MoleculA was founded in 1993.
Where is MoleculA's headquarters?
MoleculA's headquarters is located at 13884 Park Center Road, Herndon.
What is MoleculA's latest funding round?
MoleculA's latest funding round is Acquired.
Who are the investors of MoleculA?
Investors of MoleculA include International Aerospace Enterprises.